Alagille Syndrome Market Expected to rise, 2034 | Mirum Pharmaceuticals, Albireo, expected to drive market

The Alagille Syndrome market growth is driven by factors like increase in the prevalence of Alagille Syndrome, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Alagille Syndrome market report [https://www.delveinsight.com/report-store/alagille-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Alagille Syndrome market size, share, Alagille Syndrome epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alagille Syndrome market size growth forward.

Some of the key highlights from the Alagille Syndrome Market Insights Report:

*
Several key pharmaceutical companies, including Mirum Pharmaceuticals, Albireo, and others, are developing novel products to improve the Alagille Syndrome treatment outlook.

*
On September 23, 2024, Ipsen announced that the European Commission had approved Kayfanda Registered (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in patients with Alagille Syndrome (ALGS) aged six months and older. Kayfanda is a once-daily, non-systemic ileal bile acid transporter (IBAT) inhibitor. Its active ingredient, odevixibat, functions by inhibiting the ileal bile acid transporter, thereby reducing serum bile acid levels produced by the liver.

*
DelveInsight's analysis estimates that the total prevalent cases of Alagille Syndrome (ALGS) in the 7MM were approximately 17,883 in 2023, with cases expected to rise throughout the forecast period (2024-2034). This increase is attributed to growing awareness and population growth, ultimately leading to a higher prevalence of ALGS.

*
It is projected that around 38% of the total ALGS cases in the 7MM were in the United States. In 2023, the EU4 and the UK collectively accounted for approximately 9,819 prevalent cases. The total ALGS cases in the US were estimated to be around 6,824 in 2023, with a significant CAGR anticipated over the forecast period. Additionally, Japan was estimated to contribute nearly 7% of the total ALGS cases in the 7MM in 2023.

*
As per DelveInsight analysis, the Alagille Syndrome market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Alagille Syndrome Market Landscape [https://www.delveinsight.com/sample-request/alagille-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Alagille Syndrome Overview

Alagille syndrome, also referred to as Alagille-Watson syndrome, is a rare genetic disorder resulting from mutations in the JAG1 or NOTCH2 gene, with JAG1 on chromosome 20 being the most commonly affected. This autosomal dominant condition impacts multiple organ systems, with symptoms typically emerging within the first two years of life. Key features include bile duct paucity, cholestasis, jaundice, poor weight gain, severe itching, congenital heart defects, heart murmurs, vertebral anomalies, distinct facial characteristics, and ocular abnormalities. Approximately half of the cases arise de novo, meaning the mutation occurs spontaneously rather than being inherited. Symptom severity varies, and in some cases, progressive liver damage necessitates a liver transplant.

Do you know the treatment paradigms for different countries? Download our Alagille Syndrome Market Sample Report [https://www.delveinsight.com/report-store/alagille-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Alagille Syndrome Epidemiology Insights

*
In the United States, the gender-specific cases of Alagille Syndrome (ALGS) were approximately 3,846 in males and 2,978 in females in 2023. These numbers are projected to rise throughout the forecast period (2024-2034).

Alagille Syndrome Epidemiology Segmentation

DelveInsight's Alagille Syndrome market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alagille Syndrome historical patient pools and forecasted Alagille Syndrome patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alagille Syndrome Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Alagille Syndrome Prevalence

*
Age-Specific Alagille Syndrome Prevalence

*
Gender-Specific Alagille Syndrome Prevalence

*
Diagnosed and Treatable Cases of Alagille Syndrome

Visit for more @ Alagille Syndrome Epidemiological Insights [https://www.delveinsight.com/sample-request/alagille-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Alagille Syndrome Key Companies

*
Mirum Pharmaceuticals

*
Albireo, and others

For more information, visit Alagille Syndrome Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/alagille-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Alagille Syndrome Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Alagille Syndrome, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Alagille Syndrome epidemiology in the 7MM

*
Alagille Syndrome marketed and emerging therapies

*
Alagille Syndrome companies

*
Alagille Syndrome market drivers and barriers

Table of Contents:

1 Alagille Syndrome Market Key Comprehensive Insights

2 Alagille Syndrome Market Report Introduction

3 Competitive Intelligence Analysis for Alagille Syndrome

4 Alagille Syndrome Market Analysis Overview at a Glance

5 Executive Summary of Alagille Syndrome

6 Alagille Syndrome Epidemiology and Market Methodology

7 Alagille Syndrome Epidemiology and Patient Population

8 Alagille Syndrome Patient Journey

9 Alagille Syndrome Treatment Algorithm, Alagille Syndrome Current Treatment, and Medical Practices

10 Key Endpoints in Alagille Syndrome Clinical Trials

11 Alagille Syndrome Marketed Therapies

12 Alagille Syndrome Emerging Therapies

13 Alagille Syndrome: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Alagille Syndrome

16 Alagille Syndrome Market Key Opinion Leaders Reviews

18 Alagille Syndrome Market Drivers

19 Alagille Syndrome Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Alagille Syndrome Epidemiology 2034

DelveInsight's "Alagille Syndrome - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Alagille Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Alagille Syndrome Pipeline 2024

"Alagille Syndrome Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alagille Syndrome market. A detailed picture of the Alagille Syndrome pipeline landscape is provided, which includes the disease overview and Alagille Syndrome treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=alagille-syndrome-market-expected-to-rise-2034-mirum-pharmaceuticals-albireo-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.